Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product (Doxil/Caelyx, Lipodox, Myocet), By Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer, AIDS-related Kaposi’s Sarcoma), By Distribution Channel, By Region, And Segment
Description
Liposomal Doxorubicin Market Summary
The global liposomal doxorubicin market size was estimated at USD 1.31 billion in 2024 and is projected to reach USD 2.38 billion by 2033, growing at a CAGR of 7.04% from 2025 to 2033. The rising number of cancer cases, particularly breast cancer, fuels the liposomal doxorubicin market.
Advancements in nanotech for innovative drug formulations further strengthen this market. Liposomal delivery revolutionizes cancer treatment by offering increased effectiveness and lower side effects than traditional forms. Furthermore, ongoing research to improve delivery and stability and explore new therapeutic applications propels the market's rapid growth.
Rising cancer diagnoses propel the liposomal doxorubicin market, as it offers targeted chemotherapy with reduced side effects, making it a preferred treatment. For instance, the International Agency for Research on Cancer (IARC) estimates 20 million new cancer cases in 2022, projected to rise to 35 million by 2050, highlighting a growing global cancer burden.
Nano-technological advancements in the drug delivery of liposomal doxorubicin are driving the market by increasing the demand for advanced liposomal doxorubicin formulations. For instance, according to a study published in ACS Publications, Nanobowl-supported liposomal DOX (DOX@NbLipo) is more resistant towards the plasma proteins and blood flow shear force that resulted in minimal drug leakage in the drug delivery at targeted tissue. The study showed that DOX@NbLipo led to prolonged survival of the mice (up to 50 days) compared to other controls. The DOX@NbLipo treatment also led to the biggest increase in the lifespan of the mice by 108.3%.
Ongoing research on liposomal doxorubicin for different indications is propelling the market. For instance, a study published in the European Journal of Cancer demonstrated the higher efficacy of TLD-1 (Novel liposomal doxorubicin) as compared to conventional doxorubicin formulations in patients with advanced solid tumors.
Global Liposomal Doxorubicin Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liposomal doxorubicin market report based on product, application, distribution channel, and region:
The global liposomal doxorubicin market size was estimated at USD 1.31 billion in 2024 and is projected to reach USD 2.38 billion by 2033, growing at a CAGR of 7.04% from 2025 to 2033. The rising number of cancer cases, particularly breast cancer, fuels the liposomal doxorubicin market.
Advancements in nanotech for innovative drug formulations further strengthen this market. Liposomal delivery revolutionizes cancer treatment by offering increased effectiveness and lower side effects than traditional forms. Furthermore, ongoing research to improve delivery and stability and explore new therapeutic applications propels the market's rapid growth.
Rising cancer diagnoses propel the liposomal doxorubicin market, as it offers targeted chemotherapy with reduced side effects, making it a preferred treatment. For instance, the International Agency for Research on Cancer (IARC) estimates 20 million new cancer cases in 2022, projected to rise to 35 million by 2050, highlighting a growing global cancer burden.
Nano-technological advancements in the drug delivery of liposomal doxorubicin are driving the market by increasing the demand for advanced liposomal doxorubicin formulations. For instance, according to a study published in ACS Publications, Nanobowl-supported liposomal DOX (DOX@NbLipo) is more resistant towards the plasma proteins and blood flow shear force that resulted in minimal drug leakage in the drug delivery at targeted tissue. The study showed that DOX@NbLipo led to prolonged survival of the mice (up to 50 days) compared to other controls. The DOX@NbLipo treatment also led to the biggest increase in the lifespan of the mice by 108.3%.
Ongoing research on liposomal doxorubicin for different indications is propelling the market. For instance, a study published in the European Journal of Cancer demonstrated the higher efficacy of TLD-1 (Novel liposomal doxorubicin) as compared to conventional doxorubicin formulations in patients with advanced solid tumors.
Global Liposomal Doxorubicin Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liposomal doxorubicin market report based on product, application, distribution channel, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Doxil/Caelyx
- Lipodox
- Myocet
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Breast Cancer
- Ovarian Cancer
- AIDS-related Kaposi’s Sarcoma
- Multiple Myeloma
- Other Solid Tumors
- Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
125 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Liposomal Doxorubicin Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- Chapter 4. Liposomal Doxorubicin Market: Product Business Analysis
- 4.1. Product Market Share, 2024 & 2033
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Doxil/Caelyx
- 4.4.1. Doxil/Caelyx Market, 2021 - 2033 (USD Million)
- 4.5. Lipodox
- 4.5.1. Lipodox Market, 2021 - 2033 (USD Million)
- 4.6. Myocet
- 4.6.1. Myocet Market, 2021 - 2033 (USD Million)
- 4.7. Others
- 4.7.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 5. Liposomal Doxorubicin Market: Application Business Analysis
- 5.1. Application Market Share, 2024 & 2033
- 5.2. Application Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 5.4. Breast Cancer
- 5.4.1. Breast Cancer Market, 2021 - 2033 (USD Million)
- 5.5. Ovarian Cancer
- 5.5.1. Ovarian Cancer Market, 2021 - 2033 (USD Million)
- 5.6. AIDS related Kaposi’s Sarcoma
- 5.6.1. AIDS related Kaposi’s Sarcoma Market, 2021 - 2033 (USD Million)
- 5.7. Multiple Myeloma
- 5.7.1. Multiple Myeloma Market, 2021 - 2033 (USD Million)
- 5.8. Other Solid Tumors
- 5.8.1. Other Solid Tumors Market, 2021 - 2033 (USD Million)
- Chapter 6. Liposomal Doxorubicin Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2024 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
- 6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
- 6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
- Chapter 7. Liposomal Doxorubicin Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
- 7.4. North America
- 7.4.1. North America Liposomal Doxorubicin Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Mexico Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. UK Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Germany Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. France Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Italy Liposomal Doxorubici Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Spain Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Denmark Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Sweden Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Norway Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. China Liposomal DoxorubicinMarket Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. India Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Australia Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. South Korea Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Thailand Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Liposomal DoxorubicinMarket Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. China Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. South Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Saudi Arabia Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. UAE Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Kuwait Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Sun Pharmaceutical Industries Ltd.
- 8.5.1.1. Company Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Johnson & Johnson
- 8.5.2.1. Company Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Merck & Co., Inc.
- 8.5.3.1. Company Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Cipla
- 8.5.4.1. Company Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- 8.5.5.1. Company Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Lupin
- 8.5.6.1. Company Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Cadila Pharmaceuticals
- 8.5.7.1. Company Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. SRS Life Sciences
- 8.5.8.1. Company Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. GSK plc
- 8.5.9.1. Company Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Pfizer Inc.
- 8.5.10.1. Company Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
- 8.5.11. Sanofi
- 8.5.11.1. Company Overview
- 8.5.11.2. Financial Performance
- 8.5.11.3. Product Benchmarking
- 8.5.11.4. Strategic Initiatives
- 8.5.12. Sigma-Aldrich Co.
- 8.5.12.1. Company Overview
- 8.5.12.2. Financial Performance
- 8.5.12.3. Product Benchmarking
- 8.5.12.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.